Quote | Harmony Biosciences Holdings Inc. (NASDAQ:HRMY)
Last: | $29.73 |
---|---|
Change Percent: | 1.4% |
Open: | $29.55 |
Close: | $29.32 |
High: | $29.865 |
Low: | $29.4012 |
Volume: | 191,994 |
Last Trade Date Time: | 04/29/2024 03:00:00 am |
News | Harmony Biosciences Holdings Inc. (NASDAQ:HRMY)
2024-04-29 13:26:57 ET More on Harmony Biosciences Harmony Biosciences Holdings, Inc. (HRMY) Q4 2023 Earnings Call Transcript Harmony inks licensing deal for sleep disorder therapy Harmony Biosciences Non-GAAP EPS of $0.73 misses by $0.18, revenue of $168.4M in-line ...
2024-04-29 11:15:34 ET Major earnings expected before the bell on Tuesday include: Enterprise Products Partners ( EPD ) The Coca-Cola ( KO ) McDonald's ( MCD ) 3M Company ( MMM ) PayPal Holdings ( PYPL ) Read the full article on Seeking Alph...
Message Board Posts | Harmony Biosciences Holdings Inc. (NASDAQ:HRMY)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Harmony Biosciences Holdings Inc. Company Name:
HRMY Stock Symbol:
NASDAQ Market:
HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024 PR Newswire PLYMOUTH MEETING, Pa. , April 16, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2024 f...
HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST TPM-1116 preclinical data suggest a potential best-in-class profile that could transform the treatment of narcolepsy and other sleep/wake...
HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME Trial initiation a step toward potentially treating excessive daytime sleepiness and behavioral symptoms in patients with PWS PR Newswire ...